Citadel Advisors’s Enanta Pharmaceuticals ENTA Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2026
Q1 | $3.32M | Buy |
262,533
+169,375
| +182% | +$2.27M | ﹤0.01% | 5069 |
|
|
2025
Q4 | $1.47M | Buy |
+93,158
| New | +$1.18M | ﹤0.01% | 6555 |
|
|
2025
Q3 | – | Sell |
-59,144
| Closed | -$473K | – | 13075 |
|
|
2025
Q2 | $447K | Sell |
59,144
-5,782
| -9% | -$34.8K | ﹤0.01% | 8900 |
|
|
2025
Q1 | $358K | Sell |
64,926
-93,332
| -59% | -$577K | ﹤0.01% | 9194 |
|
|
2024
Q4 | $910K | Sell |
158,258
-514,622
| -76% | -$4.93M | ﹤0.01% | 7237 |
|
|
2024
Q3 | $6.97M | Buy |
672,880
+207,505
| +45% | +$2.71M | ﹤0.01% | 3433 |
|
|
2024
Q2 | $6.04M | Buy |
465,375
+409,812
| +738% | +$5.53M | ﹤0.01% | 3458 |
|
|
2024
Q1 | $970K | Sell |
55,563
-10,883
| -16% | -$144K | ﹤0.01% | 6977 |
|
|
2023
Q4 | $625K | Sell |
66,446
-129,795
| -66% | -$1.21M | ﹤0.01% | 7624 |
|
|
2023
Q3 | $2.19M | Sell |
196,241
-15,977
| -8% | -$257K | ﹤0.01% | 5055 |
|
|
2023
Q2 | $4.54M | Sell |
212,218
-78,739
| -27% | -$2.32M | ﹤0.01% | 3791 |
|
|
2023
Q1 | $11.8M | Buy |
290,957
+180,891
| +164% | +$8.64M | ﹤0.01% | 2590 |
|
|
2022
Q4 | $5.12M | Buy |
110,066
+76,104
| +224% | +$3.47M | ﹤0.01% | 3823 |
|
|
2022
Q3 | $1.76M | Buy |
+33,962
| New | +$1.98M | ﹤0.01% | 5826 |
|
|
2022
Q2 | – | Sell |
-29,972
| Closed | -$1.63M | – | 13152 |
|
|
2022
Q1 | $2.13M | Buy |
29,972
+6,771
| +29% | +$441K | ﹤0.01% | 5951 |
|
|
2021
Q4 | $1.74M | Sell |
23,201
-26,293
| -53% | -$2.06M | ﹤0.01% | 6579 |
|
|
2021
Q3 | $2.81M | Sell |
49,494
-40,253
| -45% | -$1.99M | ﹤0.01% | 5524 |
|
|
2021
Q2 | $3.95M | Sell |
89,747
-8,992
| -9% | -$440K | ﹤0.01% | 4968 |
|
|
2021
Q1 | $4.87M | Buy |
98,739
+10,810
| +12% | +$539K | ﹤0.01% | 4305 |
|
|
2020
Q4 | $3.7M | Buy |
87,929
+35,140
| +67% | +$1.55M | ﹤0.01% | 4216 |
|
|
2020
Q3 | $2.42M | Buy |
52,789
+9,904
| +23% | +$480K | ﹤0.01% | 4380 |
|
|
2020
Q2 | $2.15M | Sell |
42,885
-89,608
| -68% | -$4.64M | ﹤0.01% | 4441 |
|
|
2020
Q1 | $6.81M | Buy |
132,493
+74,579
| +129% | +$3.97M | ﹤0.01% | 2316 |
|
|
2019
Q4 | $3.58M | Sell |
57,914
-32,749
| -36% | -$2.03M | ﹤0.01% | 3543 |
|
|
2019
Q3 | $5.45M | Sell |
90,663
-175,444
| -66% | -$13M | ﹤0.01% | 2999 |
|
|
2019
Q2 | $22.5M | Buy |
266,107
+16,335
| +7% | +$1.47M | 0.01% | 1326 |
|
|
2019
Q1 | $23.9M | Buy |
249,772
+239,141
| +2,249% | +$21.5M | 0.01% | 1192 |
|
|
2018
Q4 | $753K | Buy |
10,631
+2,714
| +34% | +$208K | ﹤0.01% | 5749 |
|
|
2018
Q3 | $676K | Sell |
7,917
-11,272
| -59% | -$1.13M | ﹤0.01% | 6213 |
|
|
2018
Q2 | $2.22M | Buy |
19,189
+1,195
| +7% | +$119K | ﹤0.01% | 3938 |
|
|
2018
Q1 | $1.46M | Buy |
+17,994
| New | +$1.38M | ﹤0.01% | 4224 |
|
|
2017
Q4 | – | Sell |
-6,310
| Closed | -$316K | – | 8068 |
|
|
2017
Q3 | $295K | Buy |
+6,310
| New | +$254K | ﹤0.01% | 6099 |
|
|
2017
Q2 | – | Sell |
-18,863
| Closed | -$603K | – | 7609 |
|
|
2017
Q1 | $581K | Buy |
+18,863
| New | +$587K | ﹤0.01% | 4786 |
|
|
2015
Q4 | – | Sell |
-6,320
| Closed | -$229K | – | 8814 |
|
|
2015
Q3 | $229K | Buy |
+6,320
| New | +$271K | ﹤0.01% | 5962 |
|
|
2015
Q2 | – | Sell |
-28,639
| Closed | -$877K | – | 8796 |
|
|
2015
Q1 | $877K | Buy |
28,639
+1,743
| +6% | +$67.8K | ﹤0.01% | 4103 |
|
|
2014
Q4 | $1.37M | Sell |
26,896
-19,658
| -42% | -$880K | ﹤0.01% | 3363 |
|
|
2014
Q3 | $1.84M | Buy |
46,554
+39,333
| +545% | +$1.57M | ﹤0.01% | 2943 |
|
|
2014
Q2 | $311K | Buy |
7,221
+1,011
| +16% | +$38.6K | ﹤0.01% | 5026 |
|
|
2014
Q1 | $248K | Sell |
6,210
-3,903
| -39% | -$142K | ﹤0.01% | 5262 |
|
|
2013
Q4 | $276K | Buy |
+10,113
| New | +$245K | ﹤0.01% | 4685 |
|
Other funds holding ENTA
FCM
KAM
DTC
VCM
VPM
SSC
Citadel Advisors's ENTA Position: Q1 2026 in Review
Citadel Advisors increased its Enanta Pharmaceuticals (ENTA) stake by 182% in Q1 2026, buying an estimated $2.27M and bringing the position to 262,533 shares worth $3.32M. The position accounts for ﹤0.01% of the portfolio, ranked #5069.
Citadel Advisors first reported a position in ENTA in Q4 2013 and has held it in 40 quarters since. The position peaked at $23.9M in Q1 2019. 132 funds tracked by Wall St. Rank hold ENTA as of Q1 2026.
- Citadel Advisors held 262,533 shares of Enanta Pharmaceuticals worth $3.32M as of Q1 2026.
- Citadel Advisors bought 169,375 Enanta Pharmaceuticals shares in Q1 2026, an estimated $2.27M.
- Enanta Pharmaceuticals made up ﹤0.01% of Citadel Advisors's portfolio in Q1 2026, its #5069 holding.
- Citadel Advisors first reported a position in Enanta Pharmaceuticals in Q4 2013 and has held it in 40 quarters since.
- Citadel Advisors's Enanta Pharmaceuticals position peaked at $23.9M in Q1 2019.
- 132 funds tracked by Wall St. Rank held Enanta Pharmaceuticals as of Q1 2026.
Based on Citadel Advisors's 13F filing for Q1 2026, filed 15 May 2026.